{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-25-000111","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2025-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.743449+00:00","generated_at":"2026-05-18T00:44:57.733479+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Exelixis Q2 2025: total rev $568M, GAAP EPS $0.65; CABOMETYX NET launch, positive STELLAR-303","bullets":["Total revenues $568.3M; product revenues $520.0M (+19% YoY); collaboration rev $48.2M (down $151M due to prior-year Ipsen milestone).","GAAP net income $184.8M ($0.65 diluted EPS); non-GAAP net income $212.6M ($0.75 diluted EPS).","CABOMETYX launch in advanced NET capturing leading share, representing ~4% of Q2 CABOMETYX business.","Positive topline results from zanzalintinib STELLAR-303 study in colorectal cancer; plan to file for approval.","Early pipeline advancing: phase 1 trials for XL309, XB010, XB628; XB371 entering clinic."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-25-000111","json":"https://secwatch.observer/filing/0000939767-25-000111.json","markdown":"https://secwatch.observer/filing/0000939767-25-000111.md","text":"https://secwatch.observer/filing/0000939767-25-000111.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976725000111/0000939767-25-000111-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976725000111/exel-20250728.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T00:44:57.733479+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}